Venus Remedies declared their Q3 FY24 results on 14 Feb, 2024. The topline increased by 22.69% & the profit increased by 108.21% YoY.
As compared to the previous quarter the revenue declined by 14.49% and the profit decreased by 31.09%.
The Selling, general & administrative expenses declined by 17.75% q-o-q & increased by 21.3% Y-o-Y.
The operating income was down by 51.54% q-o-q & increased by 525% Y-o-Y.
The EPS is ₹5.13 for Q3 FY24 which increased by 108.54% Y-o-Y.
Venus Remedies has delivered -8.7% return in the last 1 week, 39.22% return in last 6 months and -10.79% YTD return.
Currently the Venus Remedies has a market cap of ₹484.42 Cr and 52wk high/low of ₹430 & ₹145.8 respectively.
As of 17 Feb, 2024 out of 1 analysts covering the company, 1 analyst has given Strong Buy rating.
The consensus recommendation as on 17 Feb, 2024 was to Strong Buy.
Venus Remedies Financials
Period | Q3 FY24 | Q2 FY24 | Q-o-Q Growth | Q3 FY23 | Y-o-Y Growth |
---|---|---|---|---|---|
Total Revenue | 143.42 | 167.72 | -14.49% | 116.9 | +22.69% |
Selling/ General/ Admin Expenses Total | 39.47 | 47.99 | -17.75% | 32.54 | +21.3% |
Depreciation/ Amortization | 6.54 | 6.44 | +1.55% | 7.22 | -9.42% |
Total Operating Expense | 137.92 | 156.37 | -11.8% | 116.02 | +18.88% |
Operating Income | 5.5 | 11.35 | -51.54% | 0.88 | +525% |
Net Income Before Taxes | 7.78 | 14.34 | -45.75% | 4.54 | +71.37% |
Net Income | 6.85 | 9.94 | -31.09% | 3.29 | +108.21% |
Diluted Normalized EPS | 5.13 | 7.44 | -31.05% | 2.46 | +108.54% |
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
MoreLess